ICML 2023 | Genetic variation in Waldenström’s macroglobulinemia: challenges and opportunities
Multiple mutations can be present in Waldenström’s macroglobulinemia (WM). Alongside the common mutation in the MYD88 gene, some patients with WM may possess a CXCR4 mutation, which can impact how they respond to treatment with BTK inhibitors. In this video, Neil Berinstein, MD, FRCPC, ABIM, Sunnybrook Research Institute, Toronto, Canada, describes these mutations and highlights the prospect of using this genetic understanding to tailor treatment to the biological profile of the patient. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultant or advisory role: AstraZeneca
Research funding: AstraZeneca, Merck, IMV
